Clinical trial · Observational
A Retrospective Study on the Treatment of Intermediate and Advanced Liver Cancer.
Retrospective Study and Construction of a Prediction Model for Patients With Intermediate and Advanced Liver Cancer Treated With TACE Combined With Immunotherapy and Targeted Therapy
NCT06205732CI-TRIAL-00073005unknownClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
To evaluate the effectiveness of TACE combined with immunotherapy and targeted therapy versus TACE alone in patients with intermediate and advanced liver cancer.
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Carcinoma, Hepatocellular | Hepatocellular Carcinoma | ONTOLOGY_EXACT | 0.98 |
Interventions
Interventions (1)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| Immunotherapy, targeted therapy. | Other | — | UNRESOLVED |
Design
Arms and outcomes
Arms (2)
- label
- TACE+PD-(L)1+TKI
- description
- Application of TACE, TKI, and immunotherapy in patients with intermediate and advanced liver cancer.
- interventionNames
- Other: Immunotherapy, targeted therapy.
- label
- TACE alone
- description
- Application of TACE in patients with intermediate and advanced liver cancer.
Primary outcomes (1)
- measure
- Progression-Free-Survival
- timeFrame
- 12 months
- description
- From date of randomization until the date of first documented progression or date of death from any cause, whichever came first.
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 18 Years
Show eligibility criteria text
Inclusion Criteria: * ≥18 years old, both men and women * primary liver cancer confirmed by liver biopsy or history of hepatitis B, AFP, and typical imaging findings * patients with liver function Child-Pugh A or B (≤8 points) * BCLC stage B and stage C * expected survival time ≥8 weeks * patients with generally good performance status (ECOG PS score 0 or 1) Exclusion Criteria: * The patient's key data is missing * liver metastatic cancer confirmed by histology or cytology * patients who interrupt treatment due to intolerance of adverse drug reactions * combined with primary malignant tumors of other organs within 5 years; combined with other serious diseases, such as severe heart disease, renal insufficiency, severe infection, bleeding, etc. * combined with systemic infection, autoimmune disease, or other types of tumors; previous allogeneic bone marrow transplantation or solid organ transplantation * study participants known to have mental illness * situations such as drug use or substance abuse
References
Publications (0)
Data not yet available
No reference posted for this study.